Get the Stockscreener App
33.13
5.78%
1.81
After Hours:
33.13
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Axogen Inc stock is traded at $33.13, with a volume of 1.13M.
It is up +5.78% in the last 24 hours and up +4.41% over the past month.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
See More
Previous Close:
$31.32
Open:
$31.53
24h Volume:
1.13M
Relative Volume:
1.21
Market Cap:
$1.72B
Revenue:
$225.21M
Net Income/Loss:
$-15.70M
P/E Ratio:
-97.84
EPS:
-0.3386
Net Cash Flow:
$-4.78M
1W Performance:
+1.59%
1M Performance:
+4.41%
6M Performance:
+85.71%
1Y Performance:
+79.08%
1-Day Range:
$31.46
$33.63
1-Week Range:
$30.00
$33.63
52-Week Range:
$9.215
$36.00
Axogen Inc Stock (AXGN) Company Profile
Name
Axogen Inc
Sector
Industry
Phone
(386) 462-6817
Address
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
33.13 | 1.63B | 225.21M | -15.70M | -4.78M | -0.3386 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Wells Fargo | Overweight |
| Dec-01-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Lake Street | Buy |
| Jul-01-24 | Initiated | Raymond James | Outperform |
| Nov-11-22 | Resumed | Jefferies | Buy |
| May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-12-19 | Initiated | Canaccord Genuity | Buy |
| Mar-02-18 | Reiterated | Lake Street | Buy |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-30-17 | Initiated | Jefferies | Buy |
| Nov-21-17 | Reiterated | Lake Street | Buy |
| Jul-31-17 | Initiated | Leerink Partners | Outperform |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-17 | Initiated | ROTH Capital | Buy |
| Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
| Nov-07-16 | Reiterated | Wedbush | Outperform |
| Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-14-14 | Initiated | Dawson James | Buy |
| Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc Stock (AXGN) Latest News
AXGN: Canaccord Genuity Maintains 'Buy' Rating with $40 Target | - GuruFocus
Risk Recap: Is Axogen Inc in a bullish channel2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
AXGN: Canaccord Genuity Maintains 'Buy' Rating with $40 Target | AXGN Stock News - gurufocus.com
AxoGen's (AXGN) "Buy" Rating Reaffirmed at Canaccord Genuity Group - MarketBeat
Do options traders know something about Axogen stock we don't? - MSN
Trading Recap: Is Axogen Inc stock influenced by commodity pricesBond Market & Real-Time Volume Analysis Alerts - baoquankhu1.vn
(AXGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Nasdaq Moves: How correlated is Axogen Inc to the S P5002026 Macro Impact & Weekly Market Pulse Updates - baoquankhu1.vn
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth - AOL.com
AxoGen, Inc. (NASDAQ:AXGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know - AOL.com
Vanguard realigns reporting; Axogen (NASDAQ: AXGN) shows 0 shares owned - Stock Titan
Assenagon Asset Management S.A. Purchases 90,777 Shares of AxoGen, Inc. $AXGN - MarketBeat
DAFNA Capital Management Sells Axogen Shares in 2025News and Statistics - IndexBox
This $6.5 Million Healthcare Reduction Follows a 71% Increase in Stock Price and 20% Rise in Revenue - Bitget
AxoGen, Inc. (NASDAQ:AXGN) Q4 2025 earnings call transcript - MSN
Is Axogen (AXGN) Fairly Priced After Strong 72.7% One Year Share Gain - Yahoo Finance
Axogen chief innovation officer DeVinney sells $171k in shares By Investing.com - Investing.com Australia
Axogen chief innovation officer DeVinney sells $171k in shares - Investing.com
Erick Wayne Devinney Sells 5,221 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
Axogen (AXGN) officer nets shares after RSU vesting and sale - Stock Titan
Axogen (AXGN) CFO nets shares from 9,000 RSU vesting as company withholds stock for taxes - Stock Titan
AxoGen Q4 2025 earnings preview - MSN
Do Options Traders Have Insights on Axogen Stock That We're Unaware Of? - Bitget
Do Options Traders Know Something About Axogen Stock We Don't? - TradingView
(AXGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
AxoGen, Inc. $AXGN is First Light Asset Management LLC's Largest Position - MarketBeat
ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN - MarketBeat
Citizens Maintains Axogen (AXGN) Market Outperform Recommendation - MSN
AXGN SEC FilingsAxogen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Axogen (AXGN) Valuation After AVANCE BLA Approval And Updated Growth Outlook - simplywall.st
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum - MarketBeat
Lake Street Initiates Coverage of Axogen (AXGN) with Buy Recommendation - MSN
Axogen at Citizens Life Sciences Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria
Axogen at Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com
AxoGen Q3 2025 Earnings Preview - MSN
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+ - MarketBeat
Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors? - simplywall.st
AxoGen at Leerink Conference: Strategic Growth and Market Expansion By Investing.com - Investing.com Nigeria
Axogen Inc Stock (AXGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axogen Inc Stock (AXGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DeVinney Erick Wayne | Chief Innovation Officer |
Mar 16 '26 |
Sale |
32.84 |
5,221 |
171,458 |
262,781 |
| Hartley Lindsey Marie | CFO |
Mar 16 '26 |
Option Exercise |
0.00 |
9,000 |
0 |
62,702 |
| Began Marc A | EVP & General Counsel |
Mar 01 '26 |
Option Exercise |
0.00 |
11,250 |
0 |
54,562 |
| Wendell Amy McBride | Director |
Dec 16 '25 |
Option Exercise |
6.91 |
43,684 |
301,963 |
137,510 |
| Wendell Amy McBride | Director |
Dec 16 '25 |
Sale |
29.31 |
43,684 |
1,280,465 |
93,826 |
| Weiler Kathy Johnson | Director |
Dec 16 '25 |
Option Exercise |
6.99 |
40,073 |
280,150 |
46,653 |
| Weiler Kathy Johnson | Director |
Dec 16 '25 |
Sale |
29.55 |
46,653 |
1,378,476 |
0 |
| Hartley Lindsey Marie | CFO |
Dec 15 '25 |
Option Exercise |
8.27 |
14,812 |
122,495 |
46,188 |
| Hartley Lindsey Marie | CFO |
Dec 15 '25 |
Sale |
29.86 |
14,812 |
442,294 |
31,376 |
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):